2022 Annual Equity Incentive Plan Grants to the Company's Executive Officers
Contract Categories:
Human Resources
- Bonus & Incentive Agreements
EX-10.2 3 a02x04x2022ex1022022annual.htm EX-10.2 Document
Exhibit 10.2
2022 Annual Equity Incentive Plan
The 2022 Annual Equity Incentive Plan provides for the issuance of equity incentive awards in the form of (i) non-qualified stock options; and (ii) time-based restricted stock units.
| Executive Officer | Time-Based Restricted Stock Units (# shares) | Non-Qualified Stock Options (# shares) | ||||||
Douglas C. Bryant President & Chief Financial Officer | 27,043 | 27,043 | ||||||
Randall J. Steward Chief Financial Officer | 14,512 | — | ||||||
Robert J. Bujarski Chief Operating Officer | 12,878 | 12,876 | ||||||
| William J. Ferenczy Senior Vice President, Cardiometabolic Business Unit | 4,958 | 4,957 | ||||||
| Michelle A. Hodges Senior Vice President, General Counsel | 6,439 | 6,438 | ||||||
Werner Kroll Senior Vice President, Research and Development | 10,642 | — | ||||||
| Tamara A. Ranalli Senior Vice President, Molecular Business Unit | 4,958 | 4,957 | ||||||
The vesting period for the non-qualified stock options and time-based restricted stock units for Section 16 officers, with the exception of Kroll and Steward, are each over four years with the first 25% of such options and RSU awards vesting at the end of the first-year anniversary of the grant date and the remainder vesting 25% annually on each of the following three anniversaries thereafter.
The awards for Steward and Kroll in 2022 are comprised entirely of time-based restricted stock units vest over three years with the first one-third vesting at the end of the first-anniversary of the grant date and the remainder vesting one-third annually on each of the following two anniversaries pursuant to the terms of such executives individual retirement programs.
